LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset (ID:20259)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol 1 Concentration | Small Mol 1 Conc Unit | Small Molecule 2 | Small Mol 2 Concentration | Small Mol 2 Conc Unit | Biological Replicate | Technical Replicate | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Dactolisib | 0.3704 | uM | Lapatinib | 1.9245 | uM | 3 | 3 | 280 | 151 | 601 | -0.4298 |
BT-20 | Alpelisib | 0.0400 | uM | Selumetinib | 10 | uM | 3 | 3 | 280 | 436 | 601 | 0.4927 |
BT-20 | Alpelisib | 10 | uM | 0 | uM | 3 | 3 | 280 | 85 | 601 | -0.6615 | |
BT-20 | Alpelisib | 0.3704 | uM | Neratinib | 1.9245 | uM | 3 | 3 | 280 | 197 | 601 | -0.2742 |
BT-20 | 0 | uM | 0 | uM | 3 | 3 | 280 | 351 | 601 | 0.2260 |